ReachX logo

Replay - ReachX Biotech & Macro Panel - Where are we with Covid-19?

Publication Date: 09 Jun 2020 - By ReachX T. By ReachX T.
Actionable
Differentiated

Multi Asset Equity Global Pharmaceuticals Biotechnology Financial Services Healthcare

 

On June 4th we discussed Covid-19's scientific perspective and impact on Healthcare Systems and Capital Markets with ReachX Advisors Dr. Graham SchoelfieldAndrew WhelanBenoit Anne and Dr. Sarah Oelsner

 

Main Topics:

 

Scientific Perspective:

  • Where do we stand with the current development in fighting the pandemic?
  • Which companies have promising approaches/ clinical trials ?

Healthcare Systems:

  • What lessons can we derive from Covid-19 in terms of impact on the healthcare systems? (UK in particular)
  • How will it affect health policies and healthcare investment?

Impact on Markets:

  • Why the market performed so well over the past few weeks?
  • How would you position yourself in the next few months?

 

The Panellists:

  • Dr. Graham Schoelfield – Managing Partner at Scitaris, a consulting firm focused on R&D strategy for pharma and biotech firms. PhD in Biochemistry and Molecular Biology.

 

  • Andrew Whelan – Strategic senior healthcare corporate finance expert and elderly care specialist. Founder and Chairman of Future Care Capital – a charity shaping thinking and practice in health and social care.

 

  • Benoit Anne – Independent Senior market strategist with a specialization in tactical asset allocation, global macro and emerging markets. Most recently Head of Public Markets Strategy & Analytics with Liberty Mutual Investments in Boston.

 

  • Dr. Sarah Oelsner – Managing Partner at Scitaris,  a consulting firm focused on R&D strategy for pharma and biotech firms. PhD in Immunology.

 

The Author

ReachX T.

Financial Writer

Financial Services

Connect

 

Most read